Microbot Medical Inc (MBOT) Stock Forecast & Price Target
Microbot Medical Inc · NASDAQ
$1.68-0.07 (-3.74%)
15-min delayed · Jul 28, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 4 firms covering Microbot Medical Inc, 4 rate it Buy or better, 0 sit at Hold, and 0 rate it Sell or worse, a strong buy consensus. The target range is very wide, $4.00 to $12.00 (about 3.0x), which points to deep disagreement over how to value the company rather than near-term timing. The average target of $6.63 sits 296% above the current $1.68. The rating mix has stayed broadly stable, with Buy-side ratings edging up from 3 to 4 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.07 next quarter toward $-0.30 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS4 ratings
Strong Buy
Strong Buy00%
Buy4100%
Hold00%
Sell00%
Strong Sell00%
Based on 4 analysts giving stock ratings to Microbot Medical Inc.
As of Jul, 4 of 4 firms rate MBOT a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
MBOT EPS & revenue forecast
EPS · NEXT QUARTER
$-0.07
Range $-0.08 – $-0.06 · 3 analysts · +5% YoY
Next period, 3 analysts expect Microbot Medical Inc to earn $-0.07 a share (range $-0.08 – $-0.06), versus $-0.07 a year earlier. Full-year consensus is $-0.28, growing to $-0.30 the year after.
REVENUE · NEXT QUARTER
$1.2M
Range $1.1M – $1.3M · 3 analysts
Revenue is expected to reach $1.2M (range $1.1M – $1.3M). Full-year consensus is $3.5M, rising to $10.6M next year.
Top analysts covering Microbot Medical Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on MBOT.
#1
Raghuram Selvaraju
HC Wainwright & Co. · Rank #249
Buy
$12.00+616.4% to target
Overall win rate
37%
+ Follow
#2
KB
Kyle Bauser
Roth Capital
Buy
$5.50+228.4% to target
Coverage
—
+ Follow
#3
AS
Anderson Schock
B. Riley Securities
Buy
$5.00+198.5% to target
Coverage
—
+ Follow
MBOT stock forecast FAQ
What is MBOT's average 12-month price target?+
The 4 analysts with a live target average $6.63 for Microbot Medical Inc over the next 12 months, ranging from a $12.00 high to a $4.00 low.
Is MBOT stock a Buy, Sell or Hold right now?+
The current consensus is Strong Buy. Of the 4 analyst ratings, 4 are Buy or Strong Buy, 0 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for MBOT?+
The Street-high target is $12.00 (HC Wainwright & Co.), and the Street-low is $4.00 (LUCID CAPITAL MARKETS). The average of all 4 active targets is $6.63.
How many Wall Street analysts cover MBOT?+
4 analysts have an active rating on Microbot Medical Inc, and 4 firms carry a live 12-month price target.
Who is the most accurate analyst covering MBOT?+
Among analysts who currently cover MBOT, Raghuram Selvaraju of HC Wainwright & Co. has the strongest overall Quantellect track record (Rank #249). Their current call is Buy with a $12.00 target.
What is Microbot Medical Inc's projected EPS for next quarter?+
The consensus estimate is $-0.07 per share (range $-0.08 – $-0.06) across 3 analysts. Full-year EPS is projected at $-0.28, rising to $-0.30 the following year.
How much revenue is Microbot Medical Inc expected to report next quarter?+
Consensus revenue is $1.2M (range $1.1M – $1.3M). Full-year revenue is projected at $3.5M, growing to $10.6M next year.
Have analysts been upgrading or downgrading MBOT lately?+
As of Jul, 4 of 4 firms rate MBOT a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their MBOT calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
LUCID CAPITAL MARKETS
